BioMarin's Earnings: Can They Turn Around?

BioMarin Pharmaceutical faces high stakes as it releases its earnings report, with investors eagerly awaiting a turnaround after missing revenue expectations in the past. Despite beating revenue targets last quarter, the company underperformed on earnings per share, leading analysts to predict just four percent growth this time around. In contrast, peers like Moderna and Biogen have seen significant revenue growth and outperformed expectations. BioMarins stock has fallen three percent over the last month, and analysts predict a price target of ninety dollars seventeen cents against the current fifty-four dollar four cent share price. The company must deliver upside to meet expectations and reverse its recent trend. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/f51a33b8134bbd47